Resveratrol vs Pterostilbene: The Clinical Breakdown
Both compounds activate overlapping longevity pathways, but they are not interchangeable. If you are trying to choose between them, the differences in bioavailability, half-life, and downstream metabolic effects matter more than most supplement guides let on.
90-second summary
Read the transcript
Resveratrol vs Pterostilbene: Which Wins? These two compounds are often treated as interchangeable, but the differences between them are real and they matter when you are deciding what to take. Both are polyphenols from the stilbene family. Both activate SIRT1, the longevity-linked enzyme tied to mitochondrial health and DNA repair. Both suppress NF-kB signaling, which drives chronic inflammation behind conditions like cardiovascular disease and neurodegeneration. The overlap is genuine. But the similarities stop at the structural level. Pterostilbene absorbs far better, reaching roughly 80% bioavailability. Resveratrol in its standard free form lands closer to one percent, because the liver rapidly breaks it down before it reaches circulation. Pterostilbene also has a half-life of seven to eight hours compared to resveratrol's one to three, meaning more active compound stays in your system longer. It also crosses the blood-brain barrier more easily, making it the more rational choice when cognitive or neuroprotective outcomes are the goal. On the other side: resveratrol carries decades of human clinical trial data behind it. If cardiovascular health and sirtuin activation are your focus, and you want a compound with a long safety record in humans, resveratrol remains the more established option. One caution with pterostilbene: at higher doses it has shown LDL increases in some participants, so monitoring is worth considering. Your goal determines which compound, or both, makes sense. Conservative doses of each can cover complementary mechanisms without redundancy. Read the full clinical breakdown at Elm and Rye to choose your stack.
What They Have in Common
Resveratrol and pterostilbene are both polyphenols from the stilbene family. Both act as sirtuin activators, specifically upregulating SIRT1, a NAD+-dependent deacetylase tied to mitochondrial biogenesis, DNA repair, and cellular stress response. Both also activate AMPK (AMP-activated protein kinase), the metabolic sensor that shifts cells toward fat oxidation and away from anabolic excess. These shared mechanisms are why both compounds appear consistently in longevity research.
They also share an anti-inflammatory profile. Both inhibit NF-kB signaling, the transcription factor that drives chronic low-grade inflammation. That pathway is implicated in nearly every age-related condition from cardiovascular disease to neurodegeneration. A 2015 review in Biochimica et Biophysica Acta confirmed both compounds modulate NF-kB activity, though through slightly different upstream mechanisms.
The similarity is real. But it stops there.
Where They Diverge
The structural difference between resveratrol and pterostilbene is small: pterostilbene has two methoxy groups where resveratrol has hydroxyl groups. That minor swap produces meaningfully different pharmacokinetics. Pterostilbene is more lipophilic, crosses cell membranes more easily, and resists hepatic metabolism far better than resveratrol does.
Oral bioavailability of resveratrol is notoriously low, often cited around 1% for free resveratrol due to rapid Phase II hepatic conjugation and gut metabolism. Pterostilbene's bioavailability in animal models runs closer to 80%, and while human data is more limited, the gap is consistent across studies. A pharmacokinetic comparison published in Molecular Nutrition and Food Research found pterostilbene had a significantly longer half-life and higher plasma retention than resveratrol at equivalent doses.
| Feature | Resveratrol | Pterostilbene |
|---|---|---|
| Bioavailability (oral) | ~1% (free form) | ~80% (animal models) |
| Half-life | 1-3 hours | 7-8 hours |
| Primary pathway | SIRT1 activation, NF-kB inhibition | SIRT1, AMPK, PPAR-alpha |
| Blood-brain barrier crossing | Limited | Higher (lipophilic) |
| Typical clinical dose | 150-500 mg/day | 50-250 mg/day |
| LDL cholesterol effect | Neutral to mildly positive | May raise LDL at high doses |
| Cost per effective dose | Lower | Higher |
| Human trial depth | Extensive | Moderate |
Pterostilbene's stronger PPAR-alpha activation also gives it a more pronounced effect on lipid metabolism and fat oxidation, which resveratrol does not replicate as cleanly. For cognitive applications, pterostilbene's better blood-brain barrier penetration makes it a more rational choice when neurological outcomes are the goal.
Resveratrol has one structural advantage: decades more human trial data. If you want the compound with the deepest clinical record, resveratrol wins on volume alone.
Who Should Pick Which
The choice depends on your primary goal, not brand loyalty. Here is how I think about it practically.
Choose resveratrol if:
- Your focus is cardiovascular health and endothelial function. The human trial data here is more mature.
- You want broad sirtuin activation at a lower per-dose cost.
- You are stacking it with an NAD+ precursor like NMN or NR, where SIRT1 synergy is the goal.
- You prefer a compound with 20+ years of human safety data.
Choose pterostilbene if:
- Cognitive function and neuroprotection are the primary targets.
- You want better plasma retention with a smaller dose. At 50-100 mg, pterostilbene may deliver more active compound than 500 mg of standard resveratrol.
- You are specifically targeting AMPK-driven metabolic effects like glucose regulation or fat oxidation.
- You have absorption issues with other polyphenols (pterostilbene's lipophilicity helps here).
Consider both if:
- You are building a longevity stack and want full-spectrum stilbene coverage.
- Doses stay conservative: 150-250 mg resveratrol with 50-100 mg pterostilbene is a reasonable pairing.
I have been running a personal experiment over the past few months, timing both compounds with my morning training sessions at the Presidio Wall tennis courts. My logic: AMPK activation and mitochondrial signaling are most relevant when paired with exercise-induced metabolic stress. I track nothing fancy, just energy consistency through long matches and how my legs feel on the third set of a 90-minute session. The pterostilbene addition at 100 mg felt like a subtle but real shift in sustained output. That is anecdotal. But it is also the kind of signal I pay attention to before trusting a mechanism on paper.
For anyone building a broader polyphenol longevity stack, it is also worth looking at Elm & Rye's fisetin supplement, which targets senescent cell clearance through a different pathway entirely. Fisetin, resveratrol, and pterostilbene hit complementary mechanisms rather than redundant ones.
My take: I use Elm & Rye's resveratrol formulation as the base of my stilbene stack because the dose is calibrated at 500 mg, which is within the range used in the most cited human trials on SIRT1 activation. The decision to use trans-resveratrol specifically (the biologically active isomer) matters here. Cis-resveratrol, which degrades more easily with light and heat exposure, is less studied and less stable.
The Reality Check
Neither compound is without limits. Resveratrol at high doses (above 1,000 mg/day) has shown pro-oxidant effects in some cell studies, which is the opposite of the intended outcome. It also inhibits CYP3A4 and CYP2C9 enzymes at higher doses, meaning it can affect how your liver processes certain medications, including blood thinners and statins.
Pterostilbene's main concern is its LDL effect. A 2014 clinical trial published in Journal of Clinical Lipidology found that pterostilbene at 100-250 mg/day raised LDL cholesterol in some participants, particularly when taken without a statin. If your cardiovascular risk profile already includes elevated LDL, that is worth monitoring.
Both compounds are generally well-tolerated at standard doses in healthy adults. Neither has strong evidence for use during pregnancy or in individuals on anticoagulant therapy without physician oversight. Expect 4-8 weeks before any measurable metabolic shift becomes apparent. These are not acute compounds.
The Bottom Line
Pterostilbene delivers more active compound per milligram and holds a pharmacokinetic edge, especially for cognitive and metabolic targets. Resveratrol has a longer human safety record and remains the better-studied option for cardiovascular and sirtuin-focused applications.
FAQ
Is pterostilbene better than resveratrol for longevity?
Pterostilbene has superior bioavailability and a longer half-life, which may make it more effective per milligram. However, resveratrol has a far deeper human clinical record, so "better" depends entirely on which outcome you are targeting and how much you weight real-world trial data versus pharmacokinetic theory.
The most practical answer is that they target overlapping but not identical pathways. Using both at conservative doses is a reasonable approach for broad longevity support.
What is the best dose of resveratrol for SIRT1 activation?
Most human trials showing measurable SIRT1 activation used doses between 150 mg and 500 mg/day of trans-resveratrol. Doses above 1,000 mg/day have not shown proportionally greater benefit and introduce a higher risk of CYP enzyme interference.
Standardized trans-resveratrol is the form used in clinical research. Avoid products that do not specify the isomer, as cis-resveratrol is less stable and less studied.
Can I take resveratrol and pterostilbene together?
Yes, combining them at moderate doses is generally considered safe and may offer complementary pathway coverage. A reasonable pairing is 150-250 mg resveratrol with 50-100 mg pterostilbene daily.
If you take any medications metabolized by CYP3A4 or CYP2C9, consult a physician before stacking either compound, as both can influence hepatic clearance at higher doses.